Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883240 · ClinicalTrials.gov registry record
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
A clinical trial of Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- 40
- Enrollment target
- 20
- Study locations
NCT06883240: Recruiting study of Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche.
NCT06883240 is a study of Von Willebrand Disease, Type 3 that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 40 participants. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06883240, a study of Von Willebrand Disease, Type 3, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.
Conditions Studied
Interventions
- DRUG Von Willebrand Factor Concentrates
- DRUG Von Willebrand Factor Concentrates and Factor VIII Concentrates
- DRUG Factor VIII Concentrates
- DRUG Recombinant Activated Factor VII
- DRUG Activated Prothrombin Complex Concentrate
Study Locations (20)
Other
- UZ Leuven Gasthuisberg - Leuven
- IPS SURA Industriales Medellín - Medellín
- Hopital Claude Huriez - CHU Lille - Lille
- Groupe Hospitalier Necker Enfants Malades - Paris
- Universitätsklinikum Bonn - Bonn
- Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz - Duisburg
- Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin - Frankfurt/M.
- Kurume University Hospital - Fukuoka
- Tokyo Medical University Hospital - Tokyo
- Erasmus MC - Rotterdam
- Instytut Hematologii i Transfuzjologii - Warsaw
California
- UC Davis - Sacramento
Florida
- University of Florida - Gainesville
Minnesota
- University of Minnesota Medical Center - Minneapolis
Missouri
- Washington University School of Medicine - St Louis
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- McGill University Health Center - Montreal
Lazio
- Universita' Degli Studi La Sapienza-Ist.Di Ematologia - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-11-01 |
What NCT06883240 shows while recruiting
NCT06883240 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 1 condition, with Von Willebrand Disease, Type 3 appearing as the primary indexed condition, and to 5 interventions - of which Von Willebrand Factor Concentrates is the first listed.
NCT06883240 names 20 study sites across 10 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06883240 about?
NCT06883240 is a clinical study titled "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment". This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy...
What is the current status of trial NCT06883240?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-04-29. Estimated completion is 2026-11-01.
What conditions does trial NCT06883240 study?
This clinical trial studies the following conditions: Von Willebrand Disease, Type 3.
What interventions are being tested in trial NCT06883240?
The interventions under investigation include: Von Willebrand Factor Concentrates (DRUG), Von Willebrand Factor Concentrates and Factor VIII Concentrates (DRUG), Factor VIII Concentrates (DRUG), Recombinant Activated Factor VII (DRUG), Activated Prothrombin Complex Concentrate (DRUG).
Who is sponsoring clinical trial NCT06883240?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883240 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease, Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI